<DOC>
	<DOCNO>NCT00696631</DOCNO>
	<brief_summary>The purpose study ass efficacy , tolerability safety dronedarone versus placebo patient symptomatic congestive heart failure ( CHF ) leave ventricular dysfunction ( LVD ) add evidence base treatment CHF .</brief_summary>
	<brief_title>European Trial Dronedarone Moderate Severe Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients hospitalize symptomatic CHF , current New York Heart Association ( NYHA ) class IIIV require treatment diuretic , within last month least 1 episode dyspnea fatigue rest , slight exertion correspond NYHA class III IV Wall motion index ( WMI ) ≤1.2 determine blinded central evaluation record standard echocardiography , equivalent leave ventricular ejection fraction ( LVEF ) ≤35 % . acute pulmonary edema within 12 hour prior start study medication various heart condition ( cardiogenic shock , obstructive valvular disease , obstructive cardiomyopathy ; acute myocardial infarction , cardiac surgery , acute myocarditis constrictive pericarditis , history torsades de pointes , bradycardia &lt; 50 bpm and/or PRinterval ≥280 m , QTcinterval &gt; 500 m , significant sinus node disease ) illness disorder CHF ( cancer metastasis , organ transplantation ) current participation another clinical study currently take investigational drug include dronedarone concomitant prohibit medication treatment class I III antiarrhythmic drug pregnant and/or breastfeed woman woman childbearing potential without adequate birth control serum potassium &lt; 3.5 mmol/L . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Heart disease</keyword>
	<keyword>morbidity</keyword>
</DOC>